<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01203254</url>
  </required_header>
  <id_info>
    <org_study_id>2009-010727-91</org_study_id>
    <nct_id>NCT01203254</nct_id>
  </id_info>
  <brief_title>Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease</brief_title>
  <acronym>COBAM</acronym>
  <official_title>Colesevelam for the Treatment of Bile Acid Malabsorption in Patients With Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florian Beigel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen, Grosshadern</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of cholestagel to reduce the frequency of
      soft and liquid stools per day in patients with CD in clinical remission with symptoms of BAM
      and to assess the improvement in stool consistency and quality of life in these patients and
      to assess the safety of cholestagel.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    insufficient enrollment
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of fluid stool &gt; 30 %</measure>
    <time_frame>4 weeks after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of Stool Consistency</measure>
    <time_frame>4 weeks after baseline</time_frame>
    <description>Proportion of patients on cholestagel compared to placebo that reaches improvement of stool consistency on the Bristol stool chart of at least one point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of Quality of Life.</measure>
    <time_frame>4 weeks after baseline</time_frame>
    <description>Proportion of patients on cholestagel compared to placebo that reaches an improvement of the Quality of Life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of median liquid or soft stool frequency/per day.</measure>
    <time_frame>4 weeks after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Crohns Disease</condition>
  <condition>Bile Acid Malabsorption</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cholestagel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <description>Colesevelam 625 mg tablet; 3 times daily 2 tablets</description>
    <arm_group_label>Cholestagel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet: 3 times daily 2 tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Signed informed consent after adequate explanation of the patient information.

          -  Male and female patients with CD and 18 to 65 years of age in clinical remission with
             a Crohns Disease Activity Index (CDAI) score of 150 or less, with symptoms of
             functional BAM or symptoms of BAM after small bowel resection with a frequency of at
             least 3 to maximal 15 liquid or soft stools per day.

          -  Stable medical treatment of CD for a minimal period of 3 months preceding the
             screening visit, consisting of

               -  either continuous oral treatment of aminosalicylate, prednisolone (a maximum 10
                  mg/day), azathioprine, 6-mercaptopurine, or methotrexate

               -  or supporting periodic treatment* with TNF-alpha AK (Infliximab, Adalimumab,
                  Certolizumab) (for patients on TNF-alpha, dosing with TNF-alpha should coincide
                  with baseline visit)

          -  Blood serum CRP value of less or equal then 1 mg/dl (10 mg/l).

          -  BAM assessed with a blood test on a 7α-hydroxy-4-cholesten-3-on excretion of equal or
             more than 50 ng/ml

        Exclusion criteria:

          -  Allergy or hypersensitivity to any of the components of cholestagel or placebo as
             identified from the medical history

          -  Participation at another clinical trial within a period of 4 weeks before the
             screening visit

          -  Presence of any addiction, alcohol abuse or specific disease that would not allow the
             patient to understand the essence and requirements and potential consequences of the
             participation to the clinical trial

          -  Signs suggestive of the patient being unable to follow the visit schedule as required
             (for example for professional obligations)

          -  Treatment with cyclosporine, or tacrolimus, 3 month or less before screening

          -  Oral Treatment with antibiotics 3 weeks or less before screening

          -  Topical treatment with steroid- or mesalazine-containing applications 3 weeks or less
             before screening

          -  Treatment with bile acid bile acid binding agent (e.g. Cholestayramine)6 weeks or less
             before screening

          -  Infectious diseases (HIV, hep B, hep C, tuberculosis, listeriosis, positive
             clostridium-difficile-toxin- proof in faeces)

          -  Current presence of intra-abdominal abscess or Fistula

          -  Cholestatic liver disease, bowel or biliary obstruction

          -  Dysphagia or swallowing disorders

          -  Known malignancy or history of malignancy

          -  Having undergone intestinal surgery within 6 months from screening

          -  Status after intestinal surgery with more then 100cm of resected bowel.

          -  Short bowel syndrome

          -  Planned -gastrostomy, ileostomy or colostomy.

          -  Pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florian Beigel, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der Universität München - Grosshadern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Praxis Dr. Mroß</name>
      <address>
        <city>Berlin</city>
        <zip>10318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hochschulambulanz Med. Klinik I - Charite-</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburgisches Forschungsinstitut für CED</name>
      <address>
        <city>Hamburg</city>
        <zip>20148</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes -Innere Medizin-</name>
      <address>
        <city>Homburg</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internistische Gemeinschaftspraxis</name>
      <address>
        <city>Leipzig</city>
        <zip>04105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CED - Zentrum der Universität München - Klinikum Grosshadern</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2010</study_first_submitted>
  <study_first_submitted_qc>September 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>April 17, 2013</last_update_submitted>
  <last_update_submitted_qc>April 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen, Grosshadern</investigator_affiliation>
    <investigator_full_name>Florian Beigel</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Colesevelam</keyword>
  <keyword>IBD</keyword>
  <keyword>Bile Acid Malabsorption</keyword>
  <keyword>Crohns disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Malabsorption Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colesevelam Hydrochloride</mesh_term>
    <mesh_term>Bile Acids and Salts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

